Tags

Type your tag names separated by a space and hit enter

Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study.
BJOG. 2022 Jan; 129(2):248-255.BJOG

Abstract

OBJECTIVE

To evaluate the impact of Covid-19 vaccination (Pfizer-BioNTech BNT162b2) during the third trimester of pregnancy on maternal and neonatal outcomes.

DESIGN

A multicentre, retrospective computerised database.

POPULATION

Women who gave birth at >24 weeks of gestation in Israel, between January and April 2021, with full records of Covid-19 disease and vaccination status.

METHODS

Women who received two doses of the vaccine were compared with unvaccinated women. Women who were recorded as having disease or a positive Covid-19 polymerase chain reaction (PCR) swab during pregnancy or delivery were excluded from both study groups. Univariate analysis was followed by multivariate logistic regression.

MAIN OUTCOME MEASURES

Composite adverse maternal outcomes. Secondary outcomes were vaccination rate and composite adverse neonatal outcomes.

RESULTS

The overall uptake of one or both vaccines was 40.2%; 712 women who received two doses of the Covid-19 vaccine were compared with 1063 unvaccinated women. Maternal composite outcomes were comparable between the groups; however, women who received the vaccine had higher rates of elective caesarean deliveries (CDs) and lower rates of vacuum deliveries. An adjusted multivariable logistic regression analysis demonstrated that Covid-19 vaccination was not associated with maternal composite adverse outcome (aOR 0.8, 95% CI 0.61-1.03); a significant reduction in the risk for neonatal composite adverse outcomes was observed (aOR 0.5, 95% CI 0.36-0.74).

CONCLUSIONS

In a motivated population covered by a National Health Insurance Plan, we found a 40.2% rate of vaccination for the Covid-19 vaccine during the third trimester of pregnancy, which was not associated with adverse maternal outcomes and, moreover, decreased the risk for neonatal adverse outcomes.

TWEETABLE ABSTRACT

Covid-19 vaccine during pregnancy is safe for both mother and fetus.

Links

PMC Free PDF

Authors+Show Affiliations

Rottenstreich M
Department of Obstetrics & Gynecology, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Department of Nursing, Jerusalem College of Technology, Jerusalem, Israel.
Sela HY
Department of Obstetrics & Gynecology, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Rotem R
Department of Obstetrics & Gynecology, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Kadish E
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Wiener-Well Y
Infectious Disease Unit, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Grisaru-Granovsky S
Department of Obstetrics & Gynecology, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

MeSH

BNT162 VaccineCOVID-19COVID-19 VaccinesCohort StudiesFemaleHumansInfant, NewbornIsraelPatient SafetyPregnancyPregnancy OutcomePregnancy Trimester, ThirdRetrospective StudiesSARS-CoV-2Treatment OutcomeVaccination

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

34554630

Citation

Rottenstreich, M, et al. "Covid-19 Vaccination During the Third Trimester of Pregnancy: Rate of Vaccination and Maternal and Neonatal Outcomes, a Multicentre Retrospective Cohort Study." BJOG : an International Journal of Obstetrics and Gynaecology, vol. 129, no. 2, 2022, pp. 248-255.
Rottenstreich M, Sela HY, Rotem R, et al. Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study. BJOG. 2022;129(2):248-255.
Rottenstreich, M., Sela, H. Y., Rotem, R., Kadish, E., Wiener-Well, Y., & Grisaru-Granovsky, S. (2022). Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study. BJOG : an International Journal of Obstetrics and Gynaecology, 129(2), 248-255. https://doi.org/10.1111/1471-0528.16941
Rottenstreich M, et al. Covid-19 Vaccination During the Third Trimester of Pregnancy: Rate of Vaccination and Maternal and Neonatal Outcomes, a Multicentre Retrospective Cohort Study. BJOG. 2022;129(2):248-255. PubMed PMID: 34554630.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study. AU - Rottenstreich,M, AU - Sela,H Y, AU - Rotem,R, AU - Kadish,E, AU - Wiener-Well,Y, AU - Grisaru-Granovsky,S, Y1 - 2021/10/06/ PY - 2021/9/5/revised PY - 2021/7/6/received PY - 2021/9/21/accepted PY - 2021/9/24/pubmed PY - 2022/1/4/medline PY - 2021/9/23/entrez KW - Covid-19 vaccine KW - healthcare coverage KW - outcome KW - pregnancy SP - 248 EP - 255 JF - BJOG : an international journal of obstetrics and gynaecology JO - BJOG VL - 129 IS - 2 N2 - OBJECTIVE: To evaluate the impact of Covid-19 vaccination (Pfizer-BioNTech BNT162b2) during the third trimester of pregnancy on maternal and neonatal outcomes. DESIGN: A multicentre, retrospective computerised database. POPULATION: Women who gave birth at >24 weeks of gestation in Israel, between January and April 2021, with full records of Covid-19 disease and vaccination status. METHODS: Women who received two doses of the vaccine were compared with unvaccinated women. Women who were recorded as having disease or a positive Covid-19 polymerase chain reaction (PCR) swab during pregnancy or delivery were excluded from both study groups. Univariate analysis was followed by multivariate logistic regression. MAIN OUTCOME MEASURES: Composite adverse maternal outcomes. Secondary outcomes were vaccination rate and composite adverse neonatal outcomes. RESULTS: The overall uptake of one or both vaccines was 40.2%; 712 women who received two doses of the Covid-19 vaccine were compared with 1063 unvaccinated women. Maternal composite outcomes were comparable between the groups; however, women who received the vaccine had higher rates of elective caesarean deliveries (CDs) and lower rates of vacuum deliveries. An adjusted multivariable logistic regression analysis demonstrated that Covid-19 vaccination was not associated with maternal composite adverse outcome (aOR 0.8, 95% CI 0.61-1.03); a significant reduction in the risk for neonatal composite adverse outcomes was observed (aOR 0.5, 95% CI 0.36-0.74). CONCLUSIONS: In a motivated population covered by a National Health Insurance Plan, we found a 40.2% rate of vaccination for the Covid-19 vaccine during the third trimester of pregnancy, which was not associated with adverse maternal outcomes and, moreover, decreased the risk for neonatal adverse outcomes. TWEETABLE ABSTRACT: Covid-19 vaccine during pregnancy is safe for both mother and fetus. SN - 1471-0528 UR - https://www.unboundmedicine.com/medline/citation/34554630/Covid_19_vaccination_during_the_third_trimester_of_pregnancy:_rate_of_vaccination_and_maternal_and_neonatal_outcomes_a_multicentre_retrospective_cohort_study_ DB - PRIME DP - Unbound Medicine ER -